Table 1 Implementation of NCCLS M100-S12 MIC breakpoints for expanded-spectrum cephalosporins tested against nonmeningeal isolates of S. pneumoniae by US clinical laboratories from January 2002 to June 2003
Number of laboratories (%) using the following breakpoints: | ||||||
|---|---|---|---|---|---|---|
Antimicrobial agent(s) | Quarter of 2002 and 2003 | Total No. of laboratories with assessable data | M100-S11 | M100-S12 | ||
no. | (%) | no. | (%) | |||
Ceftriaxone and/or cefotaxime | January-March 2002 | 216 | 168 | (77.8) | 48 | (22.2) |
April-June 2002 | 231 | 157 | (68.0) | 74 | (32.0) | |
July-September 2002 | 250 | 160 | (64.0) | 90 | (36.0) | |
October-December 2002 | 256 | 147 | (57.4) | 109 | (42.6) | |
January-March 2003 | 260 | 135 | (51.9) | 125 | (48.1) | |
April-June 2003 | 262 | 85 | (32.4) | 177 | (67.6) | |
Ceftriaxone | January-March 2002 | 119 | 93 | (78.2) | 26 | (21.8) |
April-June 2002 | 135 | 82 | (60.7) | 53 | (39.3) | |
July-September 2002 | 163 | 94 | (57.7) | 69 | (42.3) | |
October-December 2002 | 166 | 92 | (55.4) | 74 | (44.6) | |
January-March 2003 | 172 | 78 | (45.3) | 94 | (54.7) | |
April-June 2003 | 174 | 82 | (47.1) | 92 | (52.9) | |
Cefotaxime | January-March 2002 | 158 | 142 | (89.9) | 16 | (10.1) |
April-June 2002 | 168 | 143 | (85.1) | 25 | (14.9) | |
July-September 2002 | 186 | 159 | (85.5) | 27 | (14.5) | |
October-December 2002 | 196 | 141 | (71.9) | 55 | (28.1) | |
January-March 2003 | 200 | 137 | (68.5) | 63 | (31.5) | |
April-June 2003 | 200 | 96 | (48.0) | 104 | (52.0) | |